Effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial

LAMB, Kirstie Louise, LYNN, Anthony, RUSSELL, Jean and BARKER, Margo E (2020). Effect of tart cherry juice on risk of gout attacks: protocol for a randomised controlled trial. BMJ Open, 10 (3), e035108.

[img]
Preview
PDF
bmjopen-2019-035108.pdf - Published Version
Creative Commons Attribution Non-commercial.

Download (448kB) | Preview
Official URL: https://bmjopen.bmj.com/content/10/3/e035108.info
Link to published version:: https://doi.org/10.1136/bmjopen-2019-035108
Related URLs:

    Abstract

    Introduction: Gout is a painful form of inflammatory arthritis associated with several comorbidities, particularly cardiovascular disease. Cherries, which are rich in anti-inflammatory and antioxidative bioactive compounds, are proposed to be efficacious in preventing and treating gout, but recommendations to patients are conflicting. Cherry consumption has been demonstrated to lower serum urate levels and inflammation in several small studies. One observational case cross-over study reported that cherry consumption was associated with reduced risk of recurrent gout attacks. This preliminary evidence requires substantiation. The proposed randomised clinical trial aims to test the effect of consumption of tart cherry juice on risk of gout attacks. Methods and analysis: This 12-month, parallel, double-blind, randomised, placebo-controlled trial will recruit 120 individuals (aged 18–80 years) with a clinical diagnosis of gout who have self-reported a gout flare in the previous year. Participants will be randomly assigned to an intervention group, which will receive Montmorency tart cherry juice daily for a 12-month period, or a corresponding placebo group, which will receive a cherry-flavoured placebo drink. The primary study outcome is change in frequency of self-reported gout attacks. Secondary outcome measures include attack intensity, serum urate concentration, fractional excretion of uric acid, biomarkers of inflammation, blood lipids and other markers of cardiovascular risk. Other secondary outcome measures will be changes in physical activity and functional status. Statistical analysis will be conducted on an intention-to-treat basis. Ethics and dissemination: This study has been granted ethical approval by the National Research Ethics Service, Yorkshire and The Humber—Leeds West Research Ethics Committee (ref: 18/SW/0262). Results of the trial will be submitted for publication in a peer-reviewed journal. Trial registration number: NCT03621215.

    Item Type: Article
    Additional Information: ** Embargo end date: 13-03-2020 ** From BMJ via Jisc Publications Router ** Licence for this article starting on 13-03-2020: http://creativecommons.org/licenses/by-nc/4.0/ **Journal IDs: eissn 2044-6055 **Article IDs: publisher-id: bmjopen-2019-035108 **History: published_online 13-03-2020; published 03-2020; accepted 19-02-2020; rev-recd 06-01-2020; submitted 22-10-2019
    Uncontrolled Keywords: Rheumatology, 1506, 1732, rheumatology, gout, tart cherry, nutrition & dietetics, musculoskeletal disorders
    Identification Number: https://doi.org/10.1136/bmjopen-2019-035108
    Page Range: e035108
    SWORD Depositor: Colin Knott
    Depositing User: Colin Knott
    Date Deposited: 16 Mar 2020 09:37
    Last Modified: 16 Mar 2020 09:37
    URI: http://shura.shu.ac.uk/id/eprint/25985

    Actions (login required)

    View Item View Item

    Downloads

    Downloads per month over past year

    View more statistics